EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent Advances in Lipid Nanoparticles and Their Safety Concerns for mRNA Delivery

Jialiang Wang, Yaopeng Ding, Kellie Chong iD, Meng Cui, Zeyu Cao, Chenjue Tang, Zhen Tian, Yuping Hu, Yu Zhao, Shaoyi Jiang

Vaccines · 08.10.2024 · 12 (10) · 1148

DOI: 10.3390/vaccines12101148 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 08.10.2024. Verfasst von Jialiang Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA. Die Arbeit wurde bisher 257-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction: The advent of lipid nanoparticles (LNPs) as a delivery platform for mRNA therapeutics has revolutionized the biomedical field, particularly in treating infectious diseases, cancer, genetic disorders, and metabolic diseases. Recent Advances in Therapeutic LNPs: LNPs, composed of ionizable lipids, phospholipids, cholesterol, and polyethylene glycol (PEG) lipids, facilitate efficient cellular uptake and cytosolic release of mRNA while mitigating degradation by nucleases. However, as synthetic entities, LNPs face challenges that alter their therapeutic efficacy and safety concerns. Toxicity/Reactogenicity/Immunogenicity: This review provides a comprehensive overview of the latest advancements in LNP research, focusing on preclinical safety assessments encompassing toxicity, reactogenicity, and immunogenicity. Summary and Outlook: Additionally, it outlines potential strategies for addressing these challenges and offers insights into future research directions for enhancing the application of LNPs in mRNA therapeutics.

Schlagwörter

Stichwörter der Autor:innen

endosomal escapeimmunogenicitylipid nanoparticlereactogenicityselective organ-targeting LNPtoxicity

Autor:innen und Institutionen

  • Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA.
  • Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY 14853, USA.
  • Department of Materials Science and Engineering, Cornell University, Ithaca, NY 14853, USA.
  • Department of Biological and Environmental Engineering, Cornell University, Ithaca, NY 14853, USA.

ORCID-Profile: Kellie Chong

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Cancer Institute
  • Cornell University

Zitieren

APA

Wang, J., Ding, Y., Chong, K., Cui, M., Cao, Z., Tang, C., Tian, Z., Hu, Y., Zhao, Y., & Jiang, S. (2024). Recent Advances in Lipid Nanoparticles and Their Safety Concerns for mRNA Delivery. Vaccines, 12(10), 1148. https://doi.org/10.3390/vaccines12101148

Vancouver

Wang J, Ding Y, Chong K, Cui M, Cao Z, Tang C, et al. Recent Advances in Lipid Nanoparticles and Their Safety Concerns for mRNA Delivery. Vaccines. 2024;12(10):1148. doi:10.3390/vaccines12101148

BibTeX
@article{Wang2024,
  author = {Wang, Jialiang and Ding, Yaopeng and Chong, Kellie and Cui, Meng and Cao, Zeyu and Tang, Chenjue and Tian, Zhen and Hu, Yuping and Zhao, Yu and Jiang, Shaoyi},
  title = {Recent Advances in Lipid Nanoparticles and Their Safety Concerns for mRNA Delivery},
  journal = {Vaccines},
  year = {2024},
  volume = {12},
  number = {10},
  pages = {1148},
  doi = {10.3390/vaccines12101148}
}
Kostenlos starten →